China Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . China Pharma Holdings
CPHI Stock  USD 0.63  0.03  4.55%   
China Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing China Pharma's valuation are provided below:
Gross Profit
-903.3 K
Profit Margin
(0.83)
Market Capitalization
5 M
Enterprise Value Revenue
1.5993
Revenue
4.4 M
We have found one hundred twenty available fundamental signals for China Pharma Holdings, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of China Pharma Holdings prevailing fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year.

China Pharma Total Revenue

3.87 Million

Check China Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among China Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 168.4 K or Selling General Administrative of 1.5 M, as well as many indicators such as Price To Sales Ratio of 9.82, Dividend Yield of 0.0 or PTB Ratio of 4.96. China financial statements analysis is a perfect complement when working with China Pharma Valuation or Volatility modules.
  
Build AI portfolio with China Stock
Check out the analysis of China Pharma Correlation against competitors.

China Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets16.3 M17.1 M61.1 M
Slightly volatile
Short and Long Term Debt Total7.4 M4.1 M8.6 M
Pretty Stable
Other Current Liabilities2.2 M2.1 M2.7 M
Very volatile
Total Current Liabilities9 M5.8 M9.9 M
Slightly volatile
Property Plant And Equipment Net4.9 M5.2 M14.7 M
Slightly volatile
Accounts Payable245.9 K258.9 K1.4 M
Slightly volatile
Cash684.9 K720.9 K2.6 M
Slightly volatile
Non Current Assets Total12.7 M13.4 M33.6 M
Slightly volatile
Cash And Short Term Investments684.9 K720.9 K2.6 M
Slightly volatile
Net Receivables240.3 K253 K13.2 M
Slightly volatile
Common Stock Total Equity37.5 K52.4 K42.2 K
Slightly volatile
Common Stock Shares Outstanding21.1 M20.1 M7.4 M
Slightly volatile
Liabilities And Stockholders Equity16.3 M17.1 M61.1 M
Slightly volatile
Non Current Liabilities Total3.5 M2.4 M4.7 M
Pretty Stable
Other Stockholder Equity48.8 M46.5 M28.5 M
Slightly volatile
Total Liabilities12.5 M8.2 M14.7 M
Slightly volatile
Property Plant And Equipment Gross44.2 M42.1 M26.2 M
Slightly volatile
Total Current Assets2.8 M2.9 M27.4 M
Slightly volatile
Short Term Debt4.4 M2.5 M4.4 M
Pretty Stable
Common Stock37.5 K37.5 K40.3 K
Very volatile
Current Deferred Revenue138.7 K146 K769 K
Slightly volatile
Inventory1.9 M2 M9.7 M
Slightly volatile
Intangible Assets3.5 M6.4 M2.3 M
Slightly volatile
Other Liabilities718.4 K948.1 K704.4 K
Slightly volatile
Property Plant Equipment17.9 M15.4 M17.5 M
Very volatile
Net Tangible Assets5 M5.3 M53.3 M
Slightly volatile
Capital Surpluse26 M28.1 M24.2 M
Slightly volatile
Long Term Debt Total3.5 M1.9 M5 M
Slightly volatile
Short and Long Term Debt1.8 M1.9 M7.1 M
Slightly volatile
Net Invested Capital17.5 M10.2 M33.7 M
Slightly volatile
Capital Stock34.1 K29.4 K41.8 K
Pretty Stable

China Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense168.4 K177.3 K422.3 K
Pretty Stable
Selling General Administrative1.5 M1.6 M2 M
Slightly volatile
Total Revenue3.9 M4.1 M18.3 M
Slightly volatile
Other Operating Expenses12.2 M8.2 M13.5 M
Slightly volatile
Selling And Marketing Expenses452.1 K475.9 K2.2 M
Slightly volatile
Cost Of Revenue5.6 M5.9 M15 M
Slightly volatile
Non Operating Income Net Other4.9 K5.1 K132.1 K
Pretty Stable
Interest Income5.7 K6 K386.8 K
Slightly volatile
Reconciled Depreciation2.3 M2.4 M3 M
Slightly volatile

China Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.8 M1.6 M3 M
Slightly volatile
Depreciation1.9 M3 M2.4 M
Slightly volatile
End Period Cash Flow684.9 K720.9 K2.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.8210.339.5 K
Slightly volatile
Dividend Yield0.01.0E-41.0E-4
Slightly volatile
Days Sales Outstanding24.7526.05130
Slightly volatile
Average Payables870.6 K916.5 K1.6 M
Slightly volatile
Stock Based Compensation To Revenue0.01060.01110.147
Slightly volatile
Capex To Depreciation0.120.131.5862
Slightly volatile
EV To Sales10.5311.089.5 K
Slightly volatile
Inventory Turnover1.522.591.9449
Slightly volatile
Days Of Inventory On Hand243146217
Slightly volatile
Payables Turnover34.9533.2813.7197
Slightly volatile
Sales General And Administrative To Revenue0.430.450.2299
Pretty Stable
Average Inventory3.3 M3.4 M6.6 M
Slightly volatile
Research And Ddevelopement To Revenue0.04110.07210.0362
Pretty Stable
Capex To Revenue0.120.07410.0971
Slightly volatile
Cash Per Share0.03920.04130.5271
Slightly volatile
Payout Ratio0.050.05630.0614
Slightly volatile
Days Payables Outstanding10.7811.3537.8146
Slightly volatile
Intangibles To Total Assets0.450.430.1123
Slightly volatile
Current Ratio0.710.752.2205
Slightly volatile
Receivables Turnover15.2314.59.6007
Slightly volatile
Capex Per Share0.01820.01920.519
Slightly volatile
Average Receivables551.4 K580.4 K11.6 M
Slightly volatile
Revenue Per Share0.280.33.7948
Slightly volatile
Interest Debt Per Share0.180.191.731
Slightly volatile
Debt To Assets0.360.280.2932
Very volatile
Graham Number25.924.2427.1146
Very volatile
Operating Cycle163172311
Slightly volatile
Days Of Payables Outstanding10.7811.3537.8146
Slightly volatile
Dividend Payout Ratio0.050.05630.0614
Slightly volatile
Ebt Per Ebit1.260.931.756
Very volatile
Quick Ratio0.220.231.4133
Slightly volatile
Net Income Per E B T1.31.141.0035
Slightly volatile
Cash Ratio0.140.12490.2326
Slightly volatile
Cash Conversion Cycle150158277
Slightly volatile
Days Of Inventory Outstanding243146217
Slightly volatile
Days Of Sales Outstanding24.7526.05130
Slightly volatile
Fixed Asset Turnover1.091.151.8134
Slightly volatile
Debt Ratio0.360.280.2932
Very volatile
Price Sales Ratio9.8210.339.5 K
Slightly volatile
Asset Turnover0.450.350.3314
Slightly volatile

China Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap57.6 M46.8 M61.3 M
Slightly volatile
Enterprise Value61 M50.2 M64.6 M
Slightly volatile

China Fundamental Market Drivers

China Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About China Pharma Financial Statements

Investors use fundamental indicators, such as China Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although China Pharma's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue146 K138.7 K
Total Revenue4.1 M3.9 M
Cost Of Revenue5.9 M5.6 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.45  0.43 
Research And Ddevelopement To Revenue 0.07  0.04 
Capex To Revenue 0.07  0.12 
Revenue Per Share 0.30  0.28 
Ebit Per Revenue(0.91)(0.96)

Currently Active Assets on Macroaxis

FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
CSANCosan SA ADR
RKTRocket Companies
When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:
How To Invest In China
Details
Is China Stock a good investment?
Details
What is China Pharma's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of China Pharma Correlation against competitors.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is there potential for Pharmaceuticals market expansion? Will China introduce new products? Factors like these will boost the valuation of China Pharma. Projected growth potential of China fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.47)
Revenue Per Share
1.665
Quarterly Revenue Growth
0.109
Return On Assets
(0.16)
Return On Equity
(0.53)
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between China Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding China Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, China Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY